069 Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing-remitting multiple sclerosis (RRMS): subgroup analysis of advance

Abstract

IntroductionThe pivotal phase 3 ADVANCE study evaluated the efficacy of subcutaneous peginterferon beta-1a 125 mcg every 2 weeks in RRMS patients, approximately 45% of whom were newly diagnosed and had...